RIANA Therapeutics' approach to drug discovery is based on its proprietary platform technology for discovering compounds that target cancer-promoting protein-protein interactions (PPIs). Using this novel approach, RIANA is searching for inhibitors that block the formation of specific oncogenic PPIs. RIANA is currently working to develop new compounds that specifically target acute myeloid leukemia (AML) as well as other blood cancers and certain types of solid tumors.